RxSight (RXST) Expected to Announce Earnings on Thursday

RxSight (NASDAQ:RXST) is anticipated to release its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect RxSight to post earnings of ($0.19) per share and revenue of $25.63 million for the quarter. Interested persons may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Wednesday, November 5, 2025 at 4:30 PM ET.

RxSight (NASDAQ:RXST) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.04). The company had revenue of $33.64 million for the quarter, compared to analysts’ expectations of $39.78 million. RxSight had a negative return on equity of 11.56% and a negative net margin of 21.93%.The business’s quarterly revenue was down 3.7% on a year-over-year basis. During the same period in the previous year, the business posted ($0.16) EPS. On average, analysts expect RxSight to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

RxSight Stock Performance

RxSight stock opened at $8.43 on Thursday. The stock has a fifty day moving average of $8.79 and a two-hundred day moving average of $11.02. The company has a market capitalization of $344.92 million, a price-to-earnings ratio of -10.54 and a beta of 1.17. RxSight has a fifty-two week low of $6.32 and a fifty-two week high of $55.57.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Kent Lake PR LLC acquired a new position in RxSight in the second quarter valued at $3,900,000. Federated Hermes Inc. acquired a new position in RxSight in the second quarter valued at $3,397,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in RxSight by 9.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 93,382 shares of the company’s stock valued at $2,358,000 after acquiring an additional 8,424 shares during the last quarter. Canada Pension Plan Investment Board acquired a new position in RxSight in the second quarter valued at $1,846,000. Finally, Legal & General Group Plc boosted its holdings in RxSight by 5.0% in the second quarter. Legal & General Group Plc now owns 44,574 shares of the company’s stock valued at $579,000 after acquiring an additional 2,121 shares during the last quarter. Institutional investors and hedge funds own 78.78% of the company’s stock.

Analyst Ratings Changes

Several research firms have weighed in on RXST. Weiss Ratings reissued a “sell (e+)” rating on shares of RxSight in a research report on Wednesday, October 8th. Zacks Research upgraded RxSight from a “strong sell” rating to a “hold” rating in a report on Monday, September 8th. Piper Sandler decreased their price objective on RxSight from $18.00 to $10.00 and set a “neutral” rating on the stock in a report on Wednesday, July 9th. Morgan Stanley cut RxSight from an “overweight” rating to an “equal weight” rating and decreased their price objective for the stock from $20.00 to $9.00 in a report on Tuesday, July 15th. Finally, Stifel Nicolaus decreased their price objective on RxSight from $9.00 to $8.00 and set a “hold” rating on the stock in a report on Friday, August 8th. One equities research analyst has rated the stock with a Buy rating, nine have issued a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Reduce” and a consensus target price of $10.00.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.